COGT

In a report released on November 22, Christopher Liu from SVB Securities maintained a Buy rating on Cogent Biosciences (COGT - Research Report). The company's shares closed last Wednesday at $10.87.According to TipRanks, Liu is an analyst with an average return of -4.3% and a 43.90% success rate. Liu covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, Arvinas Holding Company, and Nurix Therapeutics.Currently, the analyst consensus on Cogent Biosciences is a Moderate Buy with an average price target of $18.00.See the top stocks recommended by analysts >>The company has a one-year high of $18.07 and a one-year low of $3.79.
https://www.tipranks.com/news/blurbs/cogent-biosciences-cogt-receives-a-buy-from-svb-securities-2?utm_source=advfn.com&utm_medium=referral